Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies. The regenerative therapies seek to address unmet medical needs in human health markets, focusing on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza(TM) and Sygenus. Visit www.regeneus.com.au for more information.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce that it has appointed Leo Lee as the company's new Chief Executive Officer and member of Board of Directors, effective immediately. Leo will succeed the outgoing CEO, John Martin, after 10 years of valuable service to the company.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce the State Intellectual Property Office of China has granted the Company a patent for the use of biomarkers to monitor disease progression in a patient having mesenchymal cell therapy for inflammatory conditions.
Regeneus Ltd (ASX:RGS) provides the Company's Chairman Address to Shareholders.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce John Martin, CEO, will present at the AusBiotech 2018 Conference today.
Regeneus Ltd (ASX:RGS) provides the Company's quarterly results for the period ended 30 September 2018.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to announce it has received a Notice of Intention to Grant a European patent covering the use of Progenza by the European Patent Office.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018.
Regeneus Ltd (ASX:RGS), a clinical-stage regenerative medicine company, is pleased to provide an overview of its results for the financial year ended 30 June 2018.
Your Directors present their report for Regeneus Ltd (ASX:RGS) and its controlled entities for the financial year ended 30 June 2018.
Regeneus (ASX:RGS), a clinical-stage regenerative medicine company, today announced positive results from its Phase 1 safety trial of its cancer vaccine which met the primary endpoint of safety and tolerability. The study known as the ACTIVATE trial, is the first clinical trial of RGSH4K, the company's autologous tumour vaccine product for the treatment of solid tumours.
Appendix 4G and Corporate Governance Statement
Appendix 3Z - Final Director's Interest Notice
Appendix 4D and Half-Year Report
